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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating in the work of the 
EMCDDA since 2001) as part of the national reporting process.
The most recent Selected issues are:
•  Problem amphetamine and methamphetamine use in Europe;
•  Trends in injecting drug use in Europe;
•  Drug offences: sentencing and other outcomes;
•  Polydrug use: patterns and responses.
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
•  the heads of Reitox national focal points and their staff;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, 
the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: 
http://www.emcdda.europa.eu/about/partners/reitox-network

7Introduction
The world is passing through a demographic transition, one 
of the results of which will be an increasing number of older 
people in the population. With one in five Europeans above 
the age of 60 — a proportion that is expected to increase 
— Europe is the continent with the oldest population. By 
2050, it is estimated that every fourth person in Europe will 
be older than 60 (1). As with the general population, there is 
evidence to suggest that the drug using population, 
including those who are in treatment, is also ageing. This 
would bring with it specific challenges for drug treatment 
services and increase the burden on wider health, support 
and care services.
Treatment and care for older drug users
(1) See the box ‘The greying of Europe’.
The objective of the present publication is to document the 
ageing phenomenon linked to drug use that is now being 
witnessed in Europe, and particularly the ageing of problem 
drug users. The current publication also aims to describe the 
drug use, health and social characteristics of older drug users 
and to identify their health and social needs. Current policies, 
practices and the availability of health and social responses for 
older drug users in Europe are also presented and discussed.
This Selected issue begins with a wider discussion on ageing 
and drug use in Europe, setting the context for the main 
focus of the report which is an examination of the situation 
and responses regarding older problem drug users in the 
European Union.
Sources and definitions used in this report
This Selected issue is based on a special data collection 
carried out in 13 countries (1), supplemented by data routinely 
collected by the EMCDDA and reports in the scientific literature. 
Much of the information on which this report is based is 
published in the national languages of the reporting countries, 
and has been reported to the EMCDDA as part of the Reitox 
national reports of the Member States contributing to this 
Selected issue. In general, these sources are not explicitly 
referred to in the text of this publication. The reader can refer to 
the Reitox national reports (available on the EMCDDA website) 
for a full list of sources in each country’s report.
Older drug users
There is no standard definition for ‘older drug users’ and there 
are substantial variations and understandings of the terms 
‘older’ or ‘elderly’ in the general population. Official retirement 
ages across Europe generally start at 60 years, while 
administrative and legislative frameworks across Europe 
generally consider the age of 65 as ‘elderly’.
In the drugs field, however, the cut-off point for ‘older 
individuals’ is generally much lower; in some cases as low as 
35 years old (see the box on the SDDcare project). This 
probably relates in part to the prevailing view of drug use as 
primarily a youth phenomenon. Generally, studies have used 
40 years as the cut-off point for older drug users (e.g. Beynon 
et al., 2010), while several American studies have used 50 
years or more (e.g. Lofwall et al., 2005; Rajaratnam et al., 
2009).
In the present Selected Issue, ‘older drug users’ primarily refers 
to drug users of at least one illicit substance, in and out of drug 
treatment, of at least 40 years of age. In some cases, however, 
data with a cut-off point of 40 years were not available, and 
different age ranges have been used instead.
There are two main reasons for using 40 years of age as a 
cut-off point. First, individuals who, by the age of 40, are 
dependent on drugs generally have had a long career of 
problematic drug use. Studies show that drug use exacerbates 
or accelerates conditions associated with ageing causing 
premature metabolic ageing, such as atherosclerosis or 
cardio-pulmonary ailments, among chronic drug users as young 
as 40 years old. In addition, data on drug use, related 
problems and drug treatment for individuals at an older age 
are limited across Europe. Thus, data with higher cut-off points 
were either not available or would have resulted in relatively 
few cases in the older age group.
Problem drug users
The EMCDDA defines problem drug use as ‘injecting drug use 
or long-duration/regular use of opioids, cocaine and/or 
amphetamines’ (more information is available on the EMCDDA 
website).
(1) Czech Republic, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Cyprus, Lithuania, Austria, Slovenia, United Kingdom.
8Data on which to analyse trends in cannabis use among 
older drug users since the mid-1990s exist only for a few 
European countries. Where data are available, estimates of 
last year cannabis prevalence among the 45–54 age group 
are very low. Since then, 14 countries have conducted at 
least three surveys, enabling trends over time to be 
analysed. Among these countries, two main trends can be 
observed. Five countries (Bulgaria, Hungary, Slovakia, 
Finland, Sweden) have reported low and relatively stable 
There is a widely held perception that drug use is exclusively a 
youth phenomenon, reinforced by regular mass media 
prevention campaigns commonly targeting young audiences 
and mainstream media’s repeated stories on new drugs 
consumed by party-goers. Since the publication of Winick’s 
seminal paper in 1962, it has been commonly assumed that 
people in their mid-30s ‘mature out’ of drug use. The ‘maturing 
out’ theory posits that individual and social factors associated 
with ageing processes and duration of use lead to a significant 
decline of individuals consuming drugs beyond their mid-30s.
In reality, more older people than ever are reporting 
experience with drugs at some point in their lives, and drug 
problems have no age limits. Population surveys show that 
cannabis is the illicit drug most frequently used by all age 
groups, and estimates give a total of 10 million Europeans in 
the 45–54 age group (14 % of that age group) who have 
ever used cannabis (lifetime prevalence).
It is also clear that a proportion of people do not ‘mature 
out’ of drug use as they age. While levels remain far below 
those of younger people, in the past 10 to 20 years Europe 
has witnessed increasing levels of recent drug use among 
older age groups. It is estimated that about 1 million 45- to 
54-year-olds have used cannabis in the last year, 
representing 1.6 % of the EU population in that age group. 
In the 55–64 age group, last year use is estimated at 0.5 %.
Averaged across Europe, drug use prevalence among the 
older age groups is low. The national figures, however, show 
a varied picture, with recent (last year) use of cannabis among 
the 45–54 age group reaching as high as 5 % (see Figure 1).
European prevalence levels are relatively low when 
compared with those for the United States, where 
considerably higher levels of drug use are found among 
older segments of the population. The most recent US 
survey, conducted in 2007, estimated last year use of any 
illicit drug among the 50–59 year age group at 9.4 % and 
last year use of cannabis at 5.7 % (Han et al., 2009). Less 
than 3 % of last year users initiated drug use between the 
ages of 50 and 59. Almost 90 % of last year users initiated 
drug use before the age of 30, and many had continuously 
used over the years.
Setting the scene: ageing and drug use in Europe
The greying of Europe
Since the Second World War, the Member States of the 
European Union have seen great improvements in the 
health and welfare conditions enjoyed by their populations, 
leading to falling mortality rates and increasing longevity. 
Europe experienced a post-war ‘baby boom’, with birth 
rates almost doubling in some countries. In recent decades, 
however, Europe has experienced a ‘baby bust’, with 
fertility rates falling from around 2.7 in the 1960s to about 
1.5 in the 1990s, where they have remained ever since.
These processes have resulted in the over-65s almost 
doubling as a proportion of the population in the past 60 
years (from 9 % in 1950 to 16 % in 2010) and the 
proportion under 14 decreasing by about a third (from 
25 % to 18 %), while the proportion of the population 
between 14 and 64 stayed the same (about 66 %). 
Although there are regional differences (e.g., the 
proportion of over-65s grew most in southern Europe, by a 
factor of 2.2, and the least in the north, by a factor of 1.6), 
the ageing trend is universal. By 2060, it has been 
projected, the average population age in the 27 EU 
Member States will be 47.9 years, compared to the 
average population age of 40.4 in 2008.
In addition, the proportion of the population aged 65 or 
above will also continue to increase, to a projected quarter 
of the population by 2050. It will take several decades 
before ageing starts to have a negative effect on the 
absolute size of the population, but its consequences will 
be apparent earlier, especially on the labour market and in 
the health care sector.
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Drug use behaviour has changed over the last 50 years, 
and individuals born during certain periods often share 
attitudes and behaviours, including drug-related behaviours. 
The data suggest that drug use levels among older age 
groups are strongly influenced by the ageing of cohorts with 
high levels of drug use.
In France, for example, a general population survey carried 
out in 1995 found that among the 25–34 year age group 
(those born between 1961 and 1970), use of cannabis in 
the last year was reported by 5.3 %. Ten years later, the 
same birth cohort, now aged 35–44, reported almost the 
same level of last year cannabis use (5.2 % in 2005). The 
other birth cohorts also showed relatively little change in 
cannabis use over time, as they aged. Comparing the 
different birth cohorts, though, shows that younger cohorts 
report progressively higher levels of use. For example, the 
prevalence of cannabis use reported by the 1961–70 cohort 
in 2005, when they were aged 35–44, is more than twice 
that reported by the 1951–60 cohort when they were at the 
same age (in 1995). Higher levels of cannabis use among 
younger cohorts than among older cohorts results in the 
prevalence levels of cannabis use in all age groups rising, 
as younger cohorts move into older age groups. As a result, 
the increasing trend in cannabis use observable in all age 
groups possibly reflects the ageing of younger cohorts with 
higher levels of continuous drug use. Similar patterns can be 
observed in other high-prevalence countries including 
Germany, Spain and the United Kingdom.
Birth cohort analysis, however, reveals a different pattern in 
low-prevalence countries such as Slovakia and Sweden. In 
these two countries, prevalence estimates over a ten-year 
period for age groups 35–44, 45–54 and 55–64 remained 
stable or even decreased. This suggests that there may be a 
similarly low prevalence of cannabis use across all cohorts.
In summary, the available evidence indicates that the levels of 
illicit drug use among older European citizens are increasing. 
Two different trends have been identified with regard to 
cannabis use — a gradual increase in prevalence in southern 
and western countries, and stable trends in a small number of 
low-prevalence countries. Analyses of historical data point to 
an ageing cohort containing a sizeable proportion of 
individuals who continue using illicit drugs, almost exclusively 
cannabis, into an advanced age as the main cause of this 
phenomenon. Health care providers, such as general 
practitioners and nurses, who are in regular contact with 
older people should be alert to the possibility of recreational 
or problematic drug use among their clients. As levels of 
cannabis, cocaine and synthetic drugs use among younger 
generations have reached all-time highs in many countries, 
significant increases in the numbers of drug users in the 
over-40 age groups can be anticipated in the near future.
prevalence levels (below 1 %) for last year cannabis use. 
Nine other countries, mostly from western and southern 
Europe, reported increasing trends with current prevalence 
levels ranging from 1.5 % to 5 %.
Use of other illicit drugs among the 45–54 age group is 
rarely reported, with last year use of cocaine, amphetamines 
or ecstasy in most countries estimated at close to zero, and 
nowhere above 1 %.
Figure 1: Prevalence of last year cannabis use among Europeans 
aged 45 to 54 (%)
NB: Data for the United Kingdom refer to England and Wales. Countries 
providing data for years other than 2008 are: United Kingdom (2008/09); 
Spain (2007/08); Hungary, Latvia, Portugal, Romania (2007); Ireland 
(2006/07); Germany, Cyprus, Poland, Slovakia, Finland (2006); France, 
Netherlands (2005); Belgium, Greece, Norway (2004).
Source: Reitox national focal points.
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injecting and of the development from drug use into problem 
drug use, the combination of heroin availability and 
population structure resulted in a large number of young 
people being affected by the heroin epidemic. Many of 
those who started using drugs during that time have 
continued to do so and, as with the general population, they 
have aged.
Serious negative health consequences of heroin use, in 
particular alarming increases in overdose deaths (3) and the 
detection of large HIV epidemics among drug injectors in 
many countries became apparent during the 1980s. This led 
to the adoption of measures to reduce drug-related harm, 
including the two main interventions: needle and syringe 
programmes and opioid substitution treatment (Hedrich et 
al., 2008). The modern public health approach (WHO, 
1986) recognises decision-making about health and risk as 
the responsibility of the individual, but it also understands 
that health and harm are also products of the social and 
policy environment. Following this approach, harm reduction 
efforts extended beyond giving out syringes and increasing 
treatment access, and incorporated community-based and 
‘low-threshold’ interventions, aiming at creating ‘enabling 
environments’ for risk reduction and behaviour change 
(Rhodes and Hedrich, 2010).
By 1993, needle and syringe programmes and opioid 
substitution treatment were officially in place in about half of 
all European countries, and they were scaled-up in the next 
decade, especially in north-western and southern European 
countries (Figure 2). It is estimated that, on average, 
specialised needle and syringe programmes provide a 
minimum of 80 syringes per injector per year (4). Opioid 
substitution programmes, which are now available in all EU 
Member States, had been introduced in all but one of the 
countries by 2001. It is estimated that of 1.35 million 
problem opioid users in the European Union, Croatia and 
Norway, 670 000 receive opioid substitution treatment.
Having set the scene with a review of drug use and ageing 
in Europe among the general population, the remainder of 
this Selected issue will focus on a particular group of ‘older 
people’, namely older problem drug users. The following 
section begins with a brief review of historical factors that 
have had an impact on the development of this group.
An historical perspective
An historical perspective can provide some insight into the 
likely reasons for an increase in the number of older 
problem drug users in Europe. Key factors include 
demographic changes and changing trends in heroin 
availability, alongside increased life expectancy for problem 
drug users linked to improved access to treatment and the 
development of harm reduction services.
In Europe, illicit drug use emerged as a social phenomenon 
linked to changing youth cultures during the late 1960s and 
early 1970s. The main drugs at that time were cannabis, 
LSD (lysergic acid diethylamide) and amphetamines, used 
mostly by young people in, for example, England, Germany 
and Sweden. Within these broader patterns of drug use, 
small heroin using subcultures emerged, mainly in large 
cities in north-western Europe. With increasing availability of 
heroin in the mid-1970s, use of the drug increased across 
Europe (Hartnoll, 1986), peaking during the 1980s and into 
the 1990s in western and southern European countries and 
more recently (in the 1990s to early 2000s) in eastern and 
central European countries (Hartnoll et al., 2010).
The high availability of heroin in Europe in the 1980s and 
early 1990s coincided with a large increase in young age 
groups in western and southern Europe. In 1960, the 
EU-15 (2) population aged 15 to 29 was about 73 million, 
which then increased to about 90 million in 1980 and 96 
million by 1990, followed by a decrease to about 80 million 
today. As this young age corresponds to the period of first 
Ageing and problem drug use
(2)  The 15 Member States of the EU before 2004, though in this case excluding France, as French data prior to 1980 are not available.
(3)  See Figure DRD-8 in the 2010 statistical bulletin.
(4)  Calculations based on data from 23 EU Member States and Croatia and Norway; see Table HSR-5 in the 2010 statistical bulletin. 
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Turin and 13.7/1 000 person years in Rome (Ferri et al., 
2007; Galli and Musicco, 1994; Perucci et al., 1991).
One of the results of the expansion of treatment and the 
improved chances of drug users surviving both HIV/AIDS 
and long-term problem drug use has been the increasing 
numbers of those in treatment who started using drugs in the 
1970s or 1980s. This group represents a large proportion of 
the treatment population, especially in western and southern 
European countries.
Ageing among problem drug users
The remainder of the section presents findings from the 
available data on patterns and trends regarding the ageing 
of problem drug users in Europe. It is evident that the total 
number and the proportion of older chronic, problematic 
drug users in Europe have increased significantly over the 
last decades. This ageing phenomenon can be observed 
across a number of datasets, and is particularly evident in 
An important clinical aspect of this substitution treatment is 
that due to the chronic, relapsing nature of opioid addiction, 
many clients undergo years or even decades of maintenance 
treatment with opioid substitution medications, such as 
methadone or buprenorphine.
A significant drop in HIV/AIDS related mortality was linked 
to the development of HIV protease inhibitors, which 
became available in 1996 and are a key component of 
highly active anti-retroviral therapy (HAART) for HIV/AIDS. 
Since 2004, the proportion of injecting drug users among 
HIV cases in the European Union has been declining 
(ECDC–WHO, 2009). Compared to 20 years ago, life 
expectancy after testing positive for HIV or being diagnosed 
with AIDS has increased significantly. Furthermore, for those 
with good access to health care, the time between 
seroconversion and an AIDS diagnosis has also increased. 
For example, the Italian Vedette study observed a mortality 
rate for AIDS of 2.5/1 000 person years between 1998 
and 2001, which was lower than those found in 1992 in 
two Italian mortality cohorts: 5.9/1 000 person years in 
Figure 2: Milestones in the development of harm reduction interventions for problem drug users in Europe
NB: The curves depict the number of countries officially adopting the interventions (from the EU Member States, candidate countries Croatia and Turkey, and 
Norway).
Source: EMCDDA and WHO.
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datasets allow the differentiation of age groups above 35, 
and the oldest age-bracket is 35 to 64 years old. Such a 
broad age range may indicate that the problem of ageing 
drug users had not surfaced yet at the time when the 
methodological guidelines of estimating problem drug use 
prevalence were developed in the late 1990s. However, 
recent estimates reveal that in countries where data are 
available, as many as a third of all problem drug users may 
be aged between 35 and 64.
In the United Kingdom (England), it was estimated that in 
2006 there were 332 090 individuals using opioids (mostly 
heroin) or crack cocaine, of whom 122 323 (about 27 %) 
were between 35 and 64 years old. Furthermore, the 
prevalence of problem drug users in England increased for 
older drug users (35–64) between 2004/05 and 2007/08 
from 5.77 per thousand population to 6.36 per thousand. In 
Austria, age-stratified analyses based on prevalence 
estimates show that the proportion of problem drug users 
aged above 35 increased between 2001 and 2007 from 
28 % to 33 %. In Ireland and Greece, the 35–64 age group 
represent, respectively, about a third and a quarter of all 
problem drug users.
Ageing among drug treatment clients
The growing numbers of older drug users entering 
treatment, observed by most European countries to varying 
degrees, has translated into this age group making up an 
increasing proportion of treatment entrants in most 
countries. In 2008, the EMCDDA treatment demand 
indicator collected data on more than 450 000 drug users 
entering treatment in specialised facilities, 82 000 of whom 
were aged 40 or more. This age group makes up between 
1.6 % and 28 % of treatment entrants in the 29 countries 
providing data (on average about 19 % of clients), with 11 
countries reporting less than 10 % of those entering 
treatment under the age of 40, while in eight countries this 
age group accounted for more than 20 % of treatment 
entrants (Figure 3). Less than 5 % of older drug treatment 
clients are above the age of 59.
Almost all countries where the proportion of older drug users 
is above the EU average were EU Member States before 
2004. In contrast, the eight countries with the lowest 
proportions of older drug users entering treatment all joined 
the European Union in 2004 or later.
The five biggest countries (Germany, Spain, France, Italy, 
United Kingdom) together account for 81 % of older clients 
western European countries. These countries witnessed the 
first heroin epidemics, and their older problem drug users 
are mostly chronic heroin users or clients in opioid 
substitution treatment.
Most of the available data on problem drug users in Europe 
relates to those in treatment settings — data sources 
reporting on problem drug users both inside and outside of 
treatment are confined to a limited number of national 
studies. This section draws on the EMCDDA treatment 
demand indicator and data on substitution treatment clients, 
supplemented by national studies and data on drug-induced 
deaths (5), in order to explore ageing trends among older 
problem drug users.
Looking at all problem drug users, both in and out of 
treatment, national estimates by age group are rare. The 
limited available data indicates that a sizeable proportion of 
problem drug users are over 35. Few problem drug use 
(5)  See the box ‘Sources of data on ageing among problem drug users’.
Sources of data on ageing among problem drug 
users
A small number of national studies and estimates of 
problem drug use, which focus on problem drug users both 
in and out of treatment:
•  The EMCDDA’s treatment demand indicator, which 
routinely collects data on individuals entering specialised 
drug treatment services in Europe (1). As data are not 
available for all treatment centres and cases, the 
numbers entering treatment are likely to be 
underestimated. Though overall data coverage is high, 
variation between countries may give rise to biases. It is 
also important to note that this data set refers only to 
those entering treatment in a given year and not all 
treatment clients.
•  Data on clients in substitution treatment, which to some 
extent overlap with data on clients entering drug 
treatment, but which can give further insight into the 
characteristics of opioid users in general, especially of 
those with longer drug careers.
•  Data on drug-induced deaths, which can also be used as 
an indirect indicator of changes in age of problem drug 
users.
(1)  For a description of the methods of the treatment demand 
indicator see the online EMCDDA Key indicators gateway.
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Figure 3: Drug users aged 40 or more as a proportion (%) of all treatment entrants
NB: Data are from 2008, except for Belgium (2005), Spain (2007) and Malta (2006).
Source: Reitox national focal points.
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Source: Reitox national focal points.
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to stop drug use (McLellan et al., 2000; Price, 2001). In 
addition, death rates among those who stop treatment are 
much higher than among individuals who remain in treatment 
(Brugal et al., 2005; Caplehorn et al., 1996; Davoli et al., 
1993). As a result, many patients undergo years or even 
decades of continuous or interrupted maintenance treatment, 
and many of them reach old age while in drug treatment. 
Thus, increased access to maintenance treatment has led not 
only to an increase in the number of clients in general, but 
also in the number of older clients as well.
The available evidence points to an ageing cohort of clients 
in substitution treatment in Europe. It has been estimated that 
about 670 000 clients were in substitution treatment in 
2008 in the European Union, Norway and Croatia. Almost 
all of these substitution clients are in pre-2004 EU Member 
States (98 %), with Germany, France, Italy and the United 
Kingdom together accounting for more than 60 %. Central 
and eastern European countries that joined the European 
Union since 2004 account for about 2 % of the total number 
of substitution clients.
Outpatient treatment centres in the Netherlands registered a 
slight decrease in the number of methadone clients between 
1999 and 2009 from 10 671 to 9 909 clients. The number 
and proportion of clients aged less than 40 decreased 
significantly from 6 889 clients to 2 502 during that period. 
Of the 9 909 methadone clients registered in 2009, about 
75 % were aged 40 or over, and clients aged 40–49 years 
were the largest age group, representing almost half of all 
clients in methadone treatment. However, the largest 
and 78 % of all clients. The ten countries with more than 
1 000 older clients and an above-average proportion of 
older clients, all report an increase in this proportion during 
the past decade, with Spain reporting the highest increase 
(15.1 percentage points between 2000 and 2007) 
(Figure 4). Most of the remaining 18 countries report 
below-average, though increasing, proportions of older 
drug users entering treatment. Only Greece and Cyprus 
observe a decline in the proportion of older treatment 
entrants.
Figure 4 reveals several interesting points. First, nearly all 
European countries show an increase in the proportion of 
older clients entering specialised drug treatment services 
since 2000, with the exception of Greece and Cyprus. 
Second, countries with more than 15 % of their treatment 
entrants aged 40 years or above in 2008 are almost all 
pre-2004 EU Member States (located to the right of the blue 
vertical line). Countries that joined the European Union in 
2004 or 2007 reported the lowest proportions of older 
clients in 2008. Finally, the number of older clients in 
treatment, represented by the size of the circles, correlates 
primarily with the size of the general population: the largest 
countries have the greatest numbers of older clients.
In many countries, a large proportion of older clients had 
previously been in treatment before 2008. Most of the 
countries with the highest proportion of older clients who 
had previously been in treatment are pre-2004 Member 
States — countries with drug epidemics and treatment 
systems going back a long way. One of the main reasons 
for the overall increase in the number and proportion of 
older clients is the ageing of drug users with a long drug use 
history and several treatment attempts. This trend thus 
reflects the chronic and relapsing nature of drug addiction, 
especially opioid addiction.
Equally interesting is the proportion of older problem drug 
users without an earlier treatment history. On average, 35 % 
of older drug users entering treatment across Europe are 
doing so for the first time in their lives. Many may have 
developed a drug problem later in life. In general, drug 
problems developed later in life may be less entrenched and 
could necessitate different responses.
Trends among opioid substitution 
treatment clients
Substitution treatment is the main evidence-based treatment 
for heroin dependence, and it is the treatment of choice in 
most EU countries. Among those who cease heroin use (either 
spontaneously or with the help of treatment), relapse is 
common (60–78 %), although they may have several attempts 
Figure 5: Registrations for methadone treatment in the Netherlands 
by age group, 1999–2009
NB: The graph shows the number of users registered each year for methadone 
treatment by age group (under 40, 40 to 49, 50 to 59, and 60 and over).
Source: Dutch National Alcohol and Drugs Information System (Ladis IVZ).
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the first parts of France affected by opioid use. In Denmark, 
a similar pattern can be observed. According to Danish 
reports, the heroin epidemic in that country started in the 
capital city of Copenhagen before spreading out. Now, 
several decades later, the proportion of older drug users is 
highest in the capital. Similarly, it has been estimated that 
problem opioid users aged between 35 and 64 represent 
almost 90 % of all problem opioid users in the Dutch capital, 
Amsterdam.
Increasing average age of drug-induced 
deaths
Overall, the available data on drug-induced deaths also 
point to an ageing cohort of problem opioid users in many 
EU Member States. Mortality related to drug use comprises 
the deaths caused directly or indirectly by the use of drugs. 
Direct drug-related deaths include overdoses (drug-induced 
deaths), and indirect drug-related deaths include those due 
to other causes, such as HIV/AIDS, traffic accidents, 
violence, suicide and chronic health problems caused by 
repeated use of drugs (e.g. cardiovascular problems). 
During the period 1995–2007, between 6 400 and 8 500 
drug-induced deaths were reported each year to the 
EMCDDA by EU Member States, Croatia, Turkey and 
Norway. As statistics on drug-related mortality usually 
include information on age, they can contribute to our 
understanding of ageing among drug users.
Drug users aged 40 or more make up a sizable proportion 
of all drug-induced deaths reported in the European Union. 
In the most recent data, this age group accounted for 
26.5 % of all reported drug-induced deaths, ranging from 
zero to 58 % (Figure 6). In contrast, only about one-eighth 
(13 %) of drug-induced deaths reported in Europe occur 
among those aged under 25 years. Nine of the 11 countries 
reporting higher than average proportions of older users 
among overdose deaths are pre-2004 EU Member States 
— Slovenia and Norway are the others — while the eight 
countries with the lowest proportions all joined the European 
Union since 2004. The overall mean age of women dying of 
drug overdose was higher than that of men (37.0 versus 
33.4 years).
The mean age of reported drug-induced deaths is increasing 
in many countries. Fifteen out of 17 countries for which 
comparison is possible report an upward trend in mean age 
of drug-induced deaths from the 1990s to 2008 (or most 
recent year with available information). This is especially so 
for pre-2004 EU Member States (6), though not for newer 
increase between 1999 and 2009 was observed among 
the 50- to 59-year-olds, with an almost ten-fold increase, 
from 348 clients in 1999 to 2 676 clients registered in 
2009. Decreases during that period in the size and 
proportion of younger age groups indicate that the 
Netherlands is facing an ageing of the substitution treatment 
population (Figure 5).
Data from other EU Member States reveal a similar change 
in demographics. In Denmark, approximately 1 200 
individuals (39 % of all clients in substitution treatment) aged 
40 or older were admitted to substitution treatment in 1993. 
By 2004 and 2008, this number had increased to 
approximately 2 600 (50 %) and 4 200 (55 %). In Greece, 
61 % of all clients in opioid substitution treatment in 2009 
were aged 40 or more, reflecting a five percentage point 
increase from the previous year. In other countries where 
data on substitution treatment by age are available, 
proportions of clients aged 40 or older are smaller, but are 
nonetheless increasing. For example, in Ireland the 
proportion of substitution clients over 40 years of age 
increased from 4 % of all substitution clients in 1993 to 19 % 
in 2008. In France, estimates based on various study 
populations show that about 97 000 individuals received 
high dosage buprenorphine treatment in 2008. Of these, 
29 % were aged 40 and older — an increase from 21 % in 
2002. In Austria, the number of clients in substitution 
treatment more than doubled between 2001 and 2008, and 
the proportion of those aged over 40 increased by 3.2 
percentage points (18.5 % of 4 861 clients in 2001 versus 
21.7 % of 11 119 clients in 2008).
Significant changes in the age profile of opioid users in 
treatment are not unique to Europe. A recent Australian 
study found clear evidence of both an ageing cohort of 
patients in substitution treatment and decreasing numbers of 
young entrants (Burns et al., 2009). The proportion of new 
entrants aged 40 or older increased significantly between 
1986 and 2006, and the median age of those retained in 
treatment increased with time, suggesting that a cohort of 
opioid-dependent individuals, in and out of treatment, was 
ageing in Australia.
Studies suggest that there is probably a higher proportion of 
older age groups among problem drug users in capitals and 
major cities in Europe. French social security reimbursement 
data from 2002 from 13 towns show that the proportion of 
substitution treatment clients aged 40 or older varied greatly 
from town to town, ranging from a minimum of 7.8 % in Lille 
to a maximum of 36.6 % in Paris. Paris and its suburbs were 
(6)  See Table DRD-1 (part i) and (part iii) in the 2010 statistical bulletin.
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that reported data (Figure 7), an increasing trend can be 
observed after 1999 in the proportion of cases aged 
between 40 and 59 years. This trend is more pronounced in 
the pre-2004 EU Member States, in many of which drug 
users between 40 and 59 years of age now account for 
more than 20 % of all drug-induced deaths. Among many of 
the Member States joining the EU since 2004, it is not 
possible to analyse trends in the age profile of drug-related 
deaths before 1996. However, for those countries that do 
have the historical data, upward trends are apparent.
In summary, the increase in average age in drug-induced 
deaths in Europe supports the view of an ageing cohort of 
problem drug users in many Member States. Drug 
treatment services in Europe are reporting increasing 
numbers of older clients who make up a growing 
proportion of those in treatment. It appears that the 
present generation of older problem drug users are mainly 
survivors of the drug epidemics that hit Europe during the 
1980s and 1990s surviving longer due to increased 
treatment availability, harm reduction interventions and 
anti-retroviral therapy. Nevertheless, a certain proportion 
of older users appear to have developed their drug 
problems later in life. As the number of older problem 
drug users increases across Europe, it is important to 
investigate the drug use behaviours, health and social 
characteristics of this population in order to identify their 
needs and ensure appropriate drug, health and social 
services are in place.
Member States, where variation in the data and questions 
about the reporting in earlier years do not permit 
generalisation.
Looking at how the age distribution of drug-induced deaths 
has changed over the last 10 years in those Member States 
Figure 7: Trends in the proportion of reported drug-induced 
deaths in the 40–59 age group, in selected EU Member States
Source: Reitox national focal points.
50
0
10
20
30
40
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
Sweden
Norway United 
Kingdom
France
%
Italy
Figure 6: Proportion of reported cases of drug-induced deaths 
aged 40 or more for the most recent reporting year
NB: Poland is not included as psychoactive medicines are included in their 
national definition of drug-induced deaths.
Source:  Reitox national focal points.
%
Sweden
Italy
Spain
Netherlands
Norway
Denmark
Luxembourg
European
average
United 
Kingdom
Germany
Lithuania
Turkey
France
Romania
Croatia
Greece
Finland
Austria
Cyprus
Ireland
Latvia
Malta
Slovenia
Slovakia
Czech
Republic
Hungary
Estonia
Bulgaria
0 10 20 30 40 50 60
Pre-2004 Member States
and Norway
Member States joining 
in 2004 or 2007, and 
candidate countries
17
between countries, particularly for cocaine and non-cocaine 
stimulants, both of which accounted for below-average 
proportions of older users in a large majority of countries. 
The countries reporting the highest proportions of primary 
cocaine users among older treatment entrants were Spain 
(32 %), the Netherlands (31 %) and Italy (23 %), while 
Turkey (30 %), Hungary (24 %) and France (22 %) reported 
the highest proportions of primary cannabis users among 
older entrants. Non-cocaine stimulants, mainly 
amphetamines, accounted for the highest proportions of 
older clients in the Czech Republic (57 %), Sweden (45 %) 
and Finland (24 %).
Comparing younger and older drug users, some differences 
are apparent in the distribution of treatment entrants by 
primary drug. While opioids, mainly heroin, are the most 
frequently mentioned primary drug in both age groups, they 
Having established that the numbers of older problem drug 
users are increasing in Europe, the following section 
explores in more depth the drug using behaviours of this 
group, as well as their health and social situation. Once 
again, most of the available data relates to treatment 
populations and is therefore not generalisable to all older 
problem drug users.
Drug use characteristics of older drug 
users entering treatment
Opioids, mainly heroin, were reported as the primary drug 
by the great majority (65 %) of older drug users (aged 40 or 
over) entering treatment in the European Union in 2008. 
Cocaine was the next most frequently reported primary drug 
(17 %), followed by cannabis and other drugs (both 8 %) 
and non-cocaine stimulants (4 %). These proportions varied 
Drug use, health and social characteristics of  
older problem drug users in Europe
Figure 8: Distribution of younger and older treatment entrants by primary drug for which they entered treatment
NB: Based on data for 72 228 treatment entrants aged 40 or over (older drug users) and 334 097 younger than 40 (younger drug users).
Source: Reitox national points.
OpioidsOpioids
CannabisCannabis
Other drugsOther drugs
Non-cocaine
stimulants
Non-cocaine
stimulants
Cocaine
Cocaine
Older drug usersYounger drug users
(7)  Denmark, Germany, Spain, France, Italy, Lithuania, Netherlands, Poland, Portugal, Sweden, United Kingdom.
(8) Czech Republic, Germany, Ireland, Greece, Spain, Cyprus, Austria, Slovenia.
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age of 30. In Germany and Spain about 45 % of older 
cocaine clients started to use cocaine after age 30, and in 
the Czech Republic, 39 % of older users of 
methamphetamine started using the drug at age 30 or 
above. Such ‘late-onset’ users may constitute a special 
subgroup among older drug users in a way that, compared 
to ‘early onset’ users, their drug use history is shorter and, 
thus, their treatment needs may be different.
Social situation of older drug users 
entering treatment
Older drug users are likely to suffer from the negative social 
consequences of decades of drug use. Studies report that 
older drug users are often socially excluded and isolated 
from their family, friends and social networks outside the 
drug users’ networks. They are more marginalised, have 
higher levels of unemployment, lower education, they are 
more often homeless, and they are more likely to have been 
in prison (Cassar et al., 2009; Nezet et al., 2009). Older 
drug users tend to have smaller social networks composed 
mainly of other older drug users. The causes of this include: 
having lost contact with non-drug using family and friends; 
losing peers to death; being considered a different group by 
younger drug users. In addition, they are less likely than 
younger drug users to make new friends, and are more 
prone to the loss of close friends and the associated feelings 
of depression, isolation and loneliness. Finally, the general 
quality of life of older drug users is worse than that of 
younger drug users (Lofwall et al., 2005). However, older 
drug users in treatment are reported to have better social 
conditions compared to those outside treatment.
The findings of the eight-country study undertaken for this 
report show that older drug users are often unemployed or 
economically inactive, particularly those who enter treatment 
for primary heroin use, up to 86 % of whom fall into this 
category. Users of other main substances report lower levels 
of unemployment or economic inactivity; though not falling 
below 30 % in all countries included in the analysis, the 
levels are considerably higher than in the general 
population of the same age. In the Czech Republic, where 
most clients enter treatment for primary use of 
methamphetamine, 56 % of older clients are unemployed.
Many older treatment clients live in unstable accommodation 
or in institutions, and older opioid clients in particular are 
likely to report living in precarious conditions. A significant 
proportion of older clients live alone, with reports (from the 
eight-country study) indicating a range between 23 % of 
older heroin clients in Spain and 57 % in Austria in this 
situation. Overall, older clients report living alone more 
frequently than younger clients; this finding applies to all 
are cited more often by older clients (65 %) than younger 
ones (50 %). Cannabis, in contrast, is far more frequently 
reported as the main problem drug among younger clients 
(24 %) than older clients (8 %) (Figure 8).
When looking at trends of the primary drug for which older 
drug users enter treatment in the 11 countries (7) with the 
highest increases in older clients, the proportion of primary 
opioid users aged 40 years or older increased from around 
21 % to around 30 % among all clients entering treatment 
between 2003 and 2008. The proportions of older primary 
cocaine users and primary users of stimulants other than 
cocaine also have shown notable increases. On the other 
hand, the proportion of older cannabis clients constitutes 
less than 10 % of all cannabis clients, with only a slight 
increase between 2003 and 2008.
Eight countries (8) collected data on older (aged 40 or 
above) drug treatment clients that was in addition to the 
routine EMCDDA data collection, with the aim of assessing 
patterns of drug use (route of administration, age at first 
drug use) and the socio-demographic characteristics 
(employment and living status) of older drug users. The 
results of this data collection show that most primary heroin 
using older clients inject the drug. There are, however, 
differences between countries. While the majority (between 
62 % and 88 %) of older heroin clients in the Czech 
Republic, Cyprus and Austria are injectors, in Spain and 
Ireland most (70 % and 57 %, respectively) older heroin 
users are non-injectors (they smoke or inhale). Of those 
countries providing data on a large number of older clients 
using drugs other than heroin, 25 % of older primary 
cocaine users in Germany and 89 % of older primary 
methamphetamine users in the Czech Republic reported 
injecting.
In four countries (Ireland, Spain, Austria, Slovenia) a higher 
proportion of older than younger heroin using clients are 
injectors, while in the other four countries (Czech Republic, 
Germany, Greece, Cyprus) injectors are more likely to be 
young. In addition, in the Czech Republic drug injection is 
more common among older than younger primary users of 
stimulants other than cocaine (mainly methamphetamine). 
No differences in injecting were found for other drugs.
Most of the older drug clients started using their primary 
drug between the ages of 15 and 24 years. It is likely that 
they have continuously used drugs ever since. There is, 
however, also a relatively large proportion of older drug 
treatment clients in several countries who started using their 
primary drug, regardless of the type, in their late twenties or 
after the age of 30 (‘late onset’ users). For example, in 
Germany, Ireland and Spain between 20 % and 32 % of 
older heroin users started their primary heroin use after the 
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groin (Beynon et al., 2009; Woodburn and Murie, 1996). 
Second, age-related changes in blood pressure, 
deterioration of venous valves, and a reduction of 
regenerative processes increase the risk of deep vein 
thrombosis among older injecting drug users, especially 
those who are or were heavy smokers (Beynon et al., 2009).
Infectious diseases are more common among older drug 
users than among younger ones, simply because they have 
been using drugs for longer and may have used drugs 
during times when harm reduction efforts were uncommon. 
A 2008 French survey, undertaken in all authorised low-
threshold centres (Ena CAARUD), found that the prevalence 
of HIV was almost five times higher (14 % versus 3 %) and of 
HCV about twice as high (41 % versus 23 %) among older 
drug users than among younger drug users (Toufik et al., 
2008). The treatment of infectious diseases is also more 
problematic for older drug users. Older drug users are 
disproportionately affected by failure of treatment for 
hepatitis C. This is because treatment of this disease is less 
effective when it is started at an older age, due to the 
deterioration of the immune response associated with 
ageing. This highlights the need for wider access to HCV 
testing, so that treatment can start at a younger, 
asymptomatic age when there is a better immune response.
Age-related changes in the body or medications taken for 
age-related illnesses may alter the effects of drugs. For 
example, with normal ageing there is a reduction in lean 
body mass, total body water content and kidney function. 
These physiological alterations may lead to elevated drug 
serum levels, with the result that a given amount of a drug 
may have more pronounced effects in older than in younger 
users (Dowling et al., 2008).
High levels of smoking are often observed among those with 
chronic drug problems. The respiratory complications of 
smoking, which range from a shortness of breath to 
obstructive lung disease, are more common not only among 
cigarette smokers, but also among smokers of crack cocaine, 
heroin, cannabis, and other smokeable drugs (Hser et al., 
2004). Drug use has also been shown to be a risk factor for 
earlier onset or more serious diabetes, neurological 
disorders and cancer. Older drug users may also be prone 
to falling, which is a leading cause of injury among the 
elderly and carries the risk of death. The hallucinating and 
disorienting effects of some drugs — including alcohol — 
especially when they are simultaneously taken with over-the-
counter or prescription medications, increases the risk of 
falls and accidents among older drug users (Dowling et al., 
2008; Ziere et al., 2006).
Dental deterioration is an additional serious problem among 
drug users. Insufficient dental hygiene and malnutrition often 
substances and all countries involved in the analysis. The 
difference in the living status between the two age groups 
may be due to an ageing effect, as older people in the 
general population are more likely to live alone. It may also 
be due to the higher level of social isolation and exclusion 
among older compared to younger drug users.
Physical and mental health problems 
among older drug users
Older drug users are also likely to suffer from the 
accumulated physical and mental effects of polydrug use, 
overdoses and infections. Many may suffer from physical 
handicaps or impairments acquired during their drug using 
careers. As effective therapy extends the lives of drug users, 
they become prone to conditions that normally occur with 
greater frequency among much older people, such as 
alcohol- and tobacco-related illnesses, including heart 
disease, or diabetes. In addition, they may also be affected 
by progressive conditions that may take decades to cause 
significant illness or death, such as chronic viral hepatitis.
Research suggests that ageing drug users have higher levels 
of both physical and mental health problems than either 
their peers in the general population or younger drug users. 
The reason for this is that drug use may increase the risk of 
or exacerbate conditions associated with the ageing of both 
the body and the brain (Beynon, 2009; Beynon et al., 
2009). The age-related gradual deterioration of the immune 
system, called immunosenescence, leads to a decline in the 
immune response (Gavazzi and Krause, 2002). Older drug 
users, especially those with a long history of poor health 
and living conditions, are affected to an even higher 
degree. As a result, they are more susceptible to infections 
and diseases than younger drug users or older people who 
do not use drugs (Beynon et al., 2009). In addition, due to 
the age-related changes in the body, even moderate use of 
drugs may lead to significant effects. It is estimated that the 
ageing process among older dependent drug users is 
accelerated by at least 15 years. At the age of 40, drug 
users may need a level of care corresponding to that 
required by non-substance using elderly people (Vogt, 
2009). Concurrent ageing and drug use therefore create a 
set of particular and, as of yet, not fully understood 
problems for older drug users.
Cardio-pulmonary ailments are among the serious conditions 
that are commonly found among older drug users, linked 
both to chronic tobacco smoking and long-term injecting 
drug use, which has the inevitable consequence of vein 
damage. Vein damage has two major implications. First, it 
makes injecting difficult, thus many older injectors switch to 
risky injecting practices, such as injecting into their feet or 
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A long-term follow-up study in Sweden analysed the causes 
of death of 210 opioid users; the most important of which 
were cardiovascular diseases (20 %), suicides (15 %) and 
accidents (15 %), followed by tumours (12 %, of which a 
quarter were liver tumours), liver cirrhosis (11 %) and alcohol 
or drug abuse (11 %). In this group, the documented 
average ages at death were 49 years for male and 42 
years for female opioid users, and 46 for male and 47 for 
female stimulant users (Stenbacka et al., 2010). In 
comparison, life expectancy at birth in Sweden is 79 for 
males and 83 for females (WHO, 2010).
Significant differences in the causes of deaths between 
different age groups were found in a UK study (Beynon et 
al., 2010). Compared to younger problem drug users, those 
aged 40 or over were 3.3 times more likely to die from a 
cause not directly related to their drug use. The main causes 
of deaths not related to drug use among older drug users 
were liver diseases, neoplasms, chronic lower respiratory 
infections and viral hepatitis. The authors suggest that 
attention should be given to these ‘other causes’, in 
particular the causes of death that disproportionately affect 
older drug users.
In summary, the available evidence demonstrates that a 
large majority of older drug users in Europe enter treatment 
for heroin-related problems. These are in most cases clients 
with long drug careers, with difficult living conditions and 
experience of social exclusion. Their health conditions are 
also poor and generally worse than those of younger 
treatment clients. A premature metabolic ageing is occurring 
among this population, who are also affected by a wide 
range of somatic and psychiatric conditions, resulting in a 
range of health and social needs.
lead to dental diseases that remain untreated over years and 
decades. As a result, complete loss of all teeth is not 
uncommon.
In addition to physical ailments, older drug users are 
disproportionately more affected than the general 
population by not only a higher number of, but also more 
complex and more severe psychological and psychiatric 
conditions. Anxiety, dementia, loneliness, memory problems 
and confusion are common symptoms. Furthermore, the 
prolonged use of illicit drugs has been shown to be 
associated with depression and cognitive impairments 
(Dowling et al., 2008). Stressful life events, such as the 
death of friends, which is common among older drug users, 
can not only exacerbate mental health problems but can 
also lead to an increase in more problematic or riskier drug 
use patterns.
Causes of death among older drug users
While earlier in this report data on drug-induced deaths 
were used as an indicator to demonstrate an increasingly 
ageing population of problem drug users in Europe, different 
approaches, in particular long-term longitudinal studies on 
cohorts of users, allow an insight into the most prevalent 
causes of death among drug users. These studies track 
groups of drug users (cohorts) over time and, through 
linkage with mortality registries, try to identify the causes of 
all deaths occurring in the group. Such studies can 
determine overall and cause-specific mortality rates for the 
cohort, and can estimate the group’s excess mortality 
compared to the general population (9). Specific information 
on older problem drug users, however, is scarce. In most 
published studies, only the mean age of the deceased is 
given, without any breakdown of causes by age group.
(9)  For information on mortality cohort studies see ‘Drug-related deaths and mortality’ on the EMCDDA Key indicators gateway. 
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requiring concerted action. For example, the greying of 
Europe results in an unfavourable dependency ratio with a 
larger share of the population (the elderly) becoming reliant 
on a smaller proportion of economically active adults (11). 
Thus, the ageing of the population increases the burden of 
pension provision on the economically active section of the 
community. The changing age structure also has 
implications for many policy fields including education and 
training, housing, transport and leisure. The increase in the 
size of the older generation implies greater need for 
medical treatment and health care, specialist housing 
services, mobility facilities and other public infrastructure. 
At the level of public policy, the debate on the structural 
reforms needed to take account of the implications of an 
ageing population revolves around the challenge of fiscal 
and structural adjustment.
Within this debate, questions surrounding the ageing of 
problem drug users are also relevant, but these have yet to 
be raised in many Member States. Among the specific 
points yet to be properly addressed are questions about the 
provision of welfare and the funding of care for this group. 
As it is beyond the scope of the present publication to 
review national welfare systems, a few examples based on 
the outcomes of the SDDcare project (12) are used to illustrate 
some of these problems.
Welfare is generally defined as consisting of actions or 
procedures — especially on the part of governments and 
institutions — striving to promote the basic well-being of 
individuals in need. These efforts usually strive to improve 
the financial situation of people in need, but may also strive 
to improve their employment chances and many other 
aspects of their lives, possibly including their mental health. 
Most European welfare models are based on the principles 
listed above, with some national differences. For example, 
the central principle of the German or Austrian welfare 
model is that economic development is the best way to 
Increases in the number and proportion of older problem drug 
users and the concurrent effects of chronic problem drug use, 
its associated risk behaviours and ageing present a set of new 
and significant medical, psychological and social challenges 
for policymakers and the specialised drug treatment system 
and mainstream health care and support services.
The present section attempts to document how these 
challenges are being addressed in the Member States by 
describing relevant drug and social policies, availability of 
programmes dedicated to this target group, as well as new 
developments in the treatment and care of older problem 
drug users in Europe.
Drug policies
The current EU drugs action plan (2009–12) identifies a set of 
priorities to reduce the demand for drugs, which include 
improving the coverage, quality and effectiveness of demand 
reduction interventions, i.e. prevention, treatment and harm 
reduction services. More specifically, objective 8 of the EU 
drugs action plan calls on Member States to enhance the 
quality and effectiveness of such services, taking account of 
specific needs of drug users, including those related to age. 
However, no Member State’s drug strategy or other relevant 
national drug policy document has yet made any explicit 
reference to older drug users (10). In some countries, such as 
the United Kingdom, older adults are listed among vulnerable 
groups ‘at risk’ of alcohol or drug problems, but mostly in 
relation to misuse of over-the-counter medications. In general, 
the development of specific interventions or services for older 
problem drug users has yet to be considered a priority.
Wider health and social policies relevant 
to older problem drug users
Significant demographic changes in a society often result in 
unprecedented situations with a number of questions 
Responses to older problem drug users:  
policies, treatment and care
(10)  In Austria, drug strategies exist at regional, rather than national, level. Older drug users’ needs for specific interventions are addressed in the Vorarlberg 
regional drug strategy. 
(11)  See the box ‘The greying of Europe’.
(12)  See the box ‘Senior drug dependents and care structures (SDDcare) project’.
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upon abstinence or entering rehabilitation programmes 
appears to be largely framed around the needs and 
situation of younger users. Older problem drug users who 
have a long history of treatment programmes, and for whom 
achieving long-lasting abstinence may not be a realistic 
objective, may be particularly vulnerable and poorly served 
by some drug policies and social welfare models. Similarly, 
social reintegration through participating in the labour 
market presupposes that the individuals are sufficiently 
healthy to obtain and remain in mainstream employment. 
Such premises may be true for younger problem drug users, 
but alternative social reintegration policies and options may 
have to be developed for older ones.
What services are available for older 
problem drug users?
In order to identify current practices and treatment 
programmes for older drug users, several Reitox national 
focal points conducted surveys among drug treatment 
providers or held focus groups among treatment clients in 
their country. Additional information was collected through 
the 2009 Reitox national reports and online documentation 
from the SDDcare project. It should, however, be borne in 
achieve social welfare. In these countries, social benefits are 
earnings-related, and those without employment records, 
which is particularly the case for long-term problem drug 
users, may not be entitled to the highest levels of financial 
support for health care.
Receiving financial support for drug treatment may pose 
particular problems for older drug users in some countries. 
In Germany, for example, financial support for drug 
treatment is covered to a considerable extent by pension 
funds, which operate on the principle that the costs invested 
in treating an individual’s drug problem will be recovered by 
that person’s future insurance contributions upon re-entering 
the workforce. However, it is becoming clear that the most 
vulnerable older drug users, those most in need of support, 
have health and social comorbidities that are likely to be 
incompatible with full participation in the labour market. 
Thus, continuous funding of the treatment and care for older 
drug users remains an open debate among a range of 
stakeholders in Germany.
Similar issues have been identified in Poland, where social 
support through unemployment or disability benefits require 
prolonged periods of contributions. Individual over the age 
of 30 must have at least five years of social insurance 
contributions to receive disability benefits. Among 
marginalised populations, including older problem drug 
users, most would not meet this criterion, as many will not 
have made sufficient contributions during their lifetime. As in 
many other Member States, minimum social benefits also 
exist in Poland and drug dependence is listed as one of the 
eligibility criteria. In order to obtain these benefits, drug 
users in treatment have to present the opinion of the 
conducting doctor and may lose them if there is evidence of 
drug use.
Linking drug users’ welfare support to their compliance with 
treatment has been shown in some studies to have 
potentially negative consequences. Drug users forfeiting 
their benefits were found to be, in the short term, more likely 
to turn to crime to fund their drug use (Montoya and 
Atkinson, 2002; Swartz et al., 2004). In the United 
Kingdom, a scheme was piloted whereby an individual with 
a drug problem was entitled to a ‘treatment allowance’, 
while refusal to engage with treatment could lead to benefit 
sanctions. This scheme was eventually abandoned due to 
the lack of proven benefits. The concern here is that older 
drug users may be particularly vulnerable to such sanctions, 
as their drug dependence is possibly more entrenched than 
that of young drug users.
It could be argued that the current European debate on how 
to motivate problem drug users to access treatment, improve 
their employability and provide welfare support contingent 
Senior drug dependents and care structures 
(SDDcare) project
The SDDcare project, running from 2008 to 2010 and 
partly funded by the European Union, has the aim of 
creating a knowledge base on older drug dependents, 
gathering data on the numbers involved, their life 
circumstances and health situation, and their treatment and 
care needs in four European countries (Poland, Germany, 
Scotland and Austria). During this period, national experts 
have compiled national and local epidemiological data 
from the participating countries, and information on the 
national legal and financial framework conditions relevant 
to older dependent drug users. In addition, professionals, 
national experts and older drug users have been 
interviewed in order to assess the treatment and care needs 
of this group of users. Examples of best practices in nursing 
homes and residential care in these countries have also 
been compiled. Finally, national experts from participating 
countries have drawn up a set of national and European 
recommendations on treatment and care of older drug 
users relevant to policymakers, researchers and 
professionals. 
The outcomes from this project can be found online on the 
SDDcare website.
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marked by oscillations between recovery and relapse, 
associated with deteriorating health and social conditions. 
Their life histories are thus characterised by repeated failed 
treatment attempts and, possibly, a saturation of available, 
intensive treatment offers. On these grounds, it has been 
argued that the management of their drug dependence 
should be considered as that of any other chronic condition 
for which cure is not an available option (e.g. diabetes, 
multiple sclerosis, Parkinson’s disease), but where effective 
management of the condition is achievable (Bevan, 2009). 
Standard (and expected) drug treatment objectives may 
have to be adjusted to the needs of these older clients. 
Supportive, less intensive treatment approaches not 
contingent upon abstinence may be more appropriate for 
this population. It has been argued that the development of 
more flexible expectations for older patients’ treatment 
participation and specialised programme components that 
emphasise problems common in late-life substance use 
should be pursued (Moos et al., 1995). In addition, 
unplanned discharges should be avoided and non-
compliance with treatment might best be considered in terms 
of understanding what factors lead older drug users to 
default from optimal treatment.
There is clear evidence from the literature that core 
dimensions related to quality of life, such as low 
socioeconomic status, comorbid psychiatric conditions, and 
lack of family and social supports are among the most 
important predictors of relapse (Hser, 2007; McLellan et al., 
2000; Termorshuizen et al., 2005; Weisner et al., 2003). 
Lofwall et al. (2005) showed that older methadone clients 
performed significantly worse on all scales for health-related 
quality of life when compared to general population norms 
matched for age and gender. The data presented in this 
publication support the argument that the social conditions 
of older drug users in contact with treatment services are 
poor. Thus, fostering opportunities for improved functioning 
and satisfaction in key areas (psychosocial, education, 
employment, physical and mental health, housing, leisure 
activities) may have to be prioritised and may significantly 
enhance the likelihood of sustained remission and improved 
quality of life (Laudet and Stanick, 2010; Laudet et al., 
2009).
Additionally, Gossop and Moos (2008) also raised the issue 
of pain management in ageing individuals with long 
histories of opioid dependence or receiving long-term opioid 
substitution treatment. It appears that this issue is not dealt 
with effectively due to the current lack of guidance on the 
best methods of providing palliative care for this group. The 
tendency of under-medicating people with opioid analgesics 
(known as opiophobia) is exaggerated when treating clients 
with a known drug problem or receiving substitution 
mind that this review is limited in scope and the results 
presented here can only provide a first insight into the 
availability of such services in Europe.
The available information suggests that specialised treatment 
and care programmes for older drug users are rare in 
Europe. The needs of older drug users are generally 
addressed within existing drug treatment services, and 
interventions tend to be tailored to the needs of individuals. 
Reports suggest that a small number of treatment providers 
have specialised in addressing the needs of older drug 
users, in response to the ageing of their clientele; however, 
details of such services are lacking. In addition, most 
Member States do not appear to have concrete plans to 
develop specific services for the present and future ageing 
cohorts of problem drug users.
Concerns have been voiced that current treatment and care 
services may be ill-equipped to respond adequately to the 
needs of older drug users and that certain specific services 
may be required (e.g. see Beynon, 2009). Among the 
problems identified are the orientation of current treatment 
programmes and services towards the needs of young 
problem drug users, and the likelihood that staff may be 
unfamiliar and untrained regarding late-life substance 
dependence problems as well as in dealing with health (e.g. 
reduced mobility) and social changes (e.g. isolation, loss of 
relatives) naturally occurring in older people. In addition, 
rehabilitation training is mainly geared to the needs of 
younger drug users, focusing for example on parenting skills 
and job-seeking. Increased multiple medical complications 
may make the treatment needs of older problem drug users 
somewhat different to those of younger clients. For this 
reason, treatment providers may need to expand the range 
of health care needs they address beyond those solely 
related to drug use, and appropriate adjustments in drug 
treatment may need to be made, in order to reflect age-
related changes in health status. For example, in the case of 
the ageing drug user receiving opioid substitution treatment, 
it is necessary to consider the choice of substitution 
medication, its dosage level, means of administration and 
supervision arrangements. As the number of older 
substitution clients is increasing, specific clinical guidance 
about prescribing this treatment for older clients is needed. It 
should be noted that older drug users are likely to have had 
experience of different therapeutic approaches over their 
years of receiving treatment. Their experience, maturity and 
insight into their own problem could be harnessed when 
developing individual care and treatment plans and 
prescribing regimes.
Furthermore, as a result of the chronic, relapsing nature of 
drug dependence, the career of many problem drug users is 
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goal. Half of the older adults had been abstinent during the 
last 30 days compared with 40 % of the younger adults. 
Older women, in particular, performed better than older 
males or younger women.
The outcomes for problem opioid users in methadone 
maintenance treatment have been examined in a number of 
studies. A recent US study found that older methadone 
clients (average age, 57) significantly reduced their illicit 
drug use, as indicated by fewer positive drug screens and 
lower Addiction Severity Index scores, when compared with 
the period before the same patients started methadone 
treatment. Methadone clients also scored better than 
patients who dropped out of treatment (average age, 53) 
(Fareed et al., 2009). Similar positive results were observed 
in another study comparing older and younger methadone 
clients (average ages, 53.9 and 27.7) (Lofwall et al., 2005). 
Urine toxicology results over the 16 weeks prior to study 
assessment showed that the older group had lower 
percentages of positive urine samples for opioids, cocaine, 
cannabis and benzodiazepines, with a statistically 
significant difference for opioids. A study investigating 
treatment retention of clients of structured drug treatment 
services in North West England found that the odds of 
dropping out decreased with increasing age. Older 
problem drug users were significantly more likely to stay in 
treatment for 12 weeks or longer than their younger 
counterparts (Beynon et al., 2008). Similar results were 
observed in an Australian retrospective cohort study 
investigating retention in opioid substitution treatment 
between 1985 and 2006, which found that a person aged 
40 years or older had less than half the likelihood of 
leaving treatment than someone who was less than 20 
years, if they were in the same categories on all other 
variables (Burns et al., 2009).
In summary, there is evidence to suggest that older problem 
drug users can improve how they deal with their drug 
dependence, perform better than younger problem drug 
users and tend to show good retention in treatment. 
Arguably, older people might do even better than has been 
demonstrated if designated services were available or more 
accessible, and interventions were tailored to their needs 
(Crome et al., 2009). Also, as a consequence of the limited 
amount of age-specific research carried out and published, 
the literature on drug dependence lacks empirically derived, 
proven methods for treating older dependent drug users. 
Thus, there is a clear gap in research into treatment for older 
drug users which might help to guide care providers and 
enhance treatment outcomes in this group. Consequently, 
providers have to rely on their own professional experience 
and on existing resources to address age-specific needs. On 
the positive side, however, increasing awareness about the 
treatment. Under-prescribing is mostly related to fears of 
somatic side-effects, overdosing, iatrogenic drug addiction 
or prescription drug diversion (Alford et al., 2006), and may 
result in avoidable pain for the client.
Finally, there is also the question of equipping mainstream 
geriatric and other relevant health and social services with 
the necessary skills to address the needs of older individuals 
with chronic drug-related problems, possibly including 
multiple comorbidities, who will increasingly access their 
services in the future. Staff training and awareness-raising 
among drug service providers and relevant mainstream care 
providers are likely to be important in ensuring that effective 
responses are delivered to an increasing number of older 
clients in the coming years. A greater involvement of the 
primary and secondary health care sector in providing for 
the needs of older drug users appears to be an unavoidable 
consequence of the ageing cohort.
The ageing of problem drug users is a recent phenomenon, 
and reporting Member States indicate that treatment and 
care providers do not yet offer specific programmes or 
interventions for this group. What is evident is that the extent 
of their medical, psychological and social needs require 
enhanced, multi-disciplinary and innovative approaches. An 
important next step will be the identification and assessment 
of the gaps in treatment and care provision for this target 
group and the development of an appropriate framework to 
direct clinical care, service development, training of staff 
and drug treatment models at local and national levels.
How do older drug users perform in drug 
treatment?
As noted earlier, the growing number of older clients are 
bringing along new challenges for care providers. At the 
same time, the multiple health and social needs of this group 
are placing a strain on existing resources, and the cost of 
providing care to the ageing population of older drug users 
may be considerable. For these reasons, interventions to 
improve the health and social conditions of this population 
will need to be effective and cost-efficient. However, the 
effectiveness of treatment programmes for older drug users 
is hard to determine, as research has rarely focused on 
age-related aspects and there exists only a limited number 
of studies on treatment outcomes among older drug users.
Satre et al. (2004) investigated five-year alcohol and drug 
treatment outcomes in older adults (55–77) compared to 
younger and middle-aged adults in a drug-free oriented 
programme (12-step model). At five years follow-up, older 
adults had longer retention in treatment than younger users. 
Older people were also more likely to have abstinence as a 
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there with social support and care (home care, home 
nursing). A smaller share would need supported housing 
services that include supervision, social support, practical 
aid and care. Finally, due to their frailty, it would be 
necessary to place a significant number of older drug users 
in nursing homes.
As a result, a series of ‘alternative nursing homes’ have 
been established throughout Denmark. The target clientele 
of these homes are ‘persons who, due to considerable and 
permanent physical and mental impairment of functions, 
need extensive help in ordinary, daily functions or care, 
nursing or treatment and who cannot get these needs 
covered in any other manner’ (Section 108 of the 
Consolidation Act on Social Services). Alternative nursing 
homes provide the same services as traditional nursing 
homes, but must in addition be able to accommodate 
persons with an often more active and challenging 
behaviour than the mainstream nursing home patient. Also, 
besides satisfying the need for care, the aim of these 
homes is to create a social framework for users and 
prevent social isolation.
An evaluation report provided a poignant description of the 
target clientele of these alternative nursing homes. During 
the period 2003–05, a total of 22 patients were registered. 
There were seven women and 15 men; the average age 
was 45 years; two were under the age of 35; six were 
above 50 years. They had been drug users since their 
youth, were all receiving substitution treatment, but also 
used opioids, cannabis, alcohol and benzodiazepines. 
Two-thirds of them were infected with HIV and in 
combination treatment, almost all of them had hepatitis C, 
some with complicated cirrhosis of the liver, and some had 
had tuberculosis. Furthermore, most of them had circulatory 
disorders with chronic wounds and a few had had their leg 
amputated. All of them suffered from impaired cognitive 
function, and a few were diagnosed with dementia. The 
annual mortality rate of the patients was 30 %.
Such specialised nursing homes exist in only a few EU 
Member States, and mainly as pilot projects. Although they 
cover only a very small proportion of older drug users in 
need of supervised care and accommodation, they can 
serve as useful models for future developments. The concept 
of specialised senior homes for drug users does, however, 
raise a number of questions among professionals and 
among older drug users themselves. There are concerns that 
specialised nursing homes for older drug users might have a 
negative effect on both the prospects of reintegrating 
residents and of maintaining abstinence for those who 
would wish to do so. Furthermore, it has been suggested 
that housing older drug users together could increase 
issues surrounding the drug dependence treatment of older 
adults is expected to lead to clinical trials (Schultz et al., 
2003) and outcome studies are increasingly taking age-
related aspects into account.
Accommodation and alternative nursing 
homes
With deteriorating health, limited social support and 
reduced mobility, many older problem drug users are 
faced with pressing accommodation and nursing needs. 
Due to the difficulty to accommodate older problem drug 
users in mainstream nursing or retirement homes, a few 
countries (e.g. Denmark, Germany, Netherlands) have 
developed specialised nursing homes and accommodation 
services for this group.
Two of the first such care facilities for older drug users were 
developed as pilot projects in the late 1990s in the 
Netherlands and Germany. The Dutch facility is part of an 
existing retirement home and aims to cater for older drug 
users who are no longer able to look after themselves. 
Older drug users live in 24-hour supervised 
accommodation, where the aims include helping them to 
learn and maintain living skills, manage their income, 
monitor medicine use, engage in activities and follow a 
daily routine. The main goal is to help drug users live out 
their final years in comfort and dignity. An important point 
is that while residents are encouraged to reduce their drug 
use, consumption is not prohibited.
The services provided within the German project comprise 
long-term residential care for older drug users and 
ambulatory forms of assisted living. Housed in living 
communities, older drug users can make use of outpatient 
drug treatment services and elder care. It is up to the 
project leader to decide on a case-by-case basis whether 
the services should be primarily geared to the need of the 
treatment of dependence or to aspects of nursing care. In 
Germany, several such projects have now been 
implemented as pilot projects, though do not form part of 
the regular care offer.
In 2004, the city of Copenhagen conducted a study of the 
needs for care and nursing facilities among persons over the 
age of 39 in substitution treatment and tried to assess their 
future care needs. The results suggested that about half of 
the users would start to need care and nursing services 
within five years. It was predicted that 76 % of them would 
experience somatic problems, 31 % mental disorders and 
between 30 % and 40 % social problems (social isolation, 
loneliness). The majority of older drug users lived in their 
own dwelling and were assessed to be capable of staying 
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In summary, special nursing homes for older drug users are 
regarded only as a compromise solution to urgently address 
the dire health and social needs of older and prematurely 
aged drug users. All the requirements necessary to address 
adequately the needs of a growing number of older drug 
users are, however, not fulfilled, especially in light of the 
wish for social integration and ordinary lives expressed by 
this group of citizens. Innovative approaches have therefore 
to be developed. Outpatient supported living for older drug 
users, as reported in Denmark and Germany, may already 
respond to some of the provision needs for those able and 
wishing to live in their own accommodation. All the 
evidence points to the need for a re-thinking of how we are 
currently responding to drug dependence and its 
consequences, in order to prevent at an earlier age, the 
poor health, social and legal conditions observed in today’s 
older problem drug users.
stigmatisation and exclusion from the local community (Ebert 
and Sturm, 2006, 2009).
On the other hand, it has also been argued that ordinary 
nursing homes and residential elder-care facilities are 
ill-suited to the specific needs of older (and prematurely 
aged) drug users. In support of these arguments, it is pointed 
out that elder-care staff are not trained or prepared to 
provide the counselling and psychosocial care needed by 
this special group (Ebert and Sturm, 2006, 2009). Older 
problem drug users tend to disapprove of being 
accommodated in ordinary homes for senior citizens, as 
they find their everyday routines and behavioural patterns 
are often incompatible with the daily organisation of such 
homes. Furthermore, continued drug use and potential 
criminal behaviour linked to the illicit nature of their 
dependence would be likely to cause problems (Ebert and 
Sturm, 2006). In addition, older drug users are reported to 
be apprehensive of the prejudices of residents not familiar 
with drug problems, and fear stigmatisation (Vogt, 2009).
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As drug epidemics there occurred later than in western and 
southern Europe, these regions can expect, over the next 
decades, to see increasing numbers of older problem drug 
users. Against this, though, important developments in the 
past 20 to 30 years may suggest a different long-term 
prospect. Among these are demographic change (a 
declining number of young people in most European 
countries), changes in drug availability and consumption 
(more cocaine, less heroin than in the 1980s and 1990s), 
significant improvements in availability, access and quality 
of treatment and harm reduction services in Europe. These 
may lead to a levelling off in the number of new treatment 
entrants and better health and social conditions for future 
older problem drug users.
Furthermore, many of those with a long and severe history of 
drug dependence are socially isolated and marginalised. 
Older drug treatment entrants report high levels of 
unemployment, and many of them live alone. Family ties 
have probably been severed during their long drug using 
career. Their social networks diminish as they age and as 
older drug using friends die.
Older drug users are also likely to experience the 
detrimental and cumulative effects of long-term drug use on 
their physical and mental health. Many develop a range of 
chronic and life-threatening conditions resulting in premature 
ageing. And, there are indications of certain types of deaths 
not related to drug use being disproportionally high among 
this group compared to younger drug users or same age 
non-drug using individuals. Taken together, their long-term 
drug dependence and poor health and social conditions 
indicate that older problem drug users experience a poor 
quality of life.
The severity of these needs — drug-related and others — 
presents new challenges for specialised drug services, and 
for mainstream health and social care providers in Europe.
A review of health and social responses for older drug users 
in Europe revealed that older drug users are not yet 
considered of particular policy importance, despite their 
growing number. With the exception of a number of pilot 
projects for alternative retirement homes for older drug 
This Selected issue presents for the first time an overview of 
the situation of older drug users in Europe, and more 
particularly that of older problem drug users. This 
publication briefly reviews drug use by older people in the 
general population and then goes on to address three main 
questions. First, to what extent is the European problem drug 
using population ageing? Secondly, what are the 
characteristics of older problem drug users in terms of drug 
use, health and social conditions? And finally, what are the 
current policies, practices and availability of health and 
social responses for older drug users in Europe?
Among the older age groups in the general population, 
there are clear signs that cannabis use has been increasing 
over the past decades, at least in western and southern 
European countries. One concern for the future, highlighted 
in the present publication, is that recent high levels of drug 
use among younger generations may continue as higher 
levels of drug use among older generations in years to 
come.
Particularly worrying is the fact that data from several 
indicators show that the number of older problem drug users 
in Europe has also increased. For example, data from 
specialised drug treatment centres and for opioid substitution 
treatment indicate that drug users aged 40 years or more 
constitute a substantial proportion of the overall population 
in these services. On average, older drug users represent 
almost 20 % of drug treatment entrants in Europe, and close 
to 30 % in some countries. This represents a major increase 
compared to ten years ago, when these figures did not 
exceed 10 % in most countries. National data on opioid 
substitution treatment corroborate these findings, with some 
countries reporting that more than half of the clients in 
opioid substitution treatment are aged 40 or more. As with 
drug use in the general population, relatively high 
proportions of older problem drug users are mostly 
observed in western and southern European countries. Many 
of these ageing drug users first became dependent during 
the heroin epidemics in these countries in the 1980s and 
1990s. In most central and eastern European countries, 
users aged 40 or over continue to make up small to 
moderate proportions of the problem drug using population. 
Overall findings
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inform professionals and service providers, researchers must 
turn their attention to investigating the needs of older drug 
users and determining what constitutes adequate responses 
for this target group. Aspects surrounding quality of life, 
treatment care and social reintegration of older clients in 
long-term opioid substitution treatment stand out as research 
priorities.
For service providers, the need to adapt existing services to 
an ageing drug using population is inevitable. Integrating 
geriatrics in drug treatment staff training and raising 
awareness about drug addiction among mainstream health 
providers for the elderly are important starting points. As a 
consequence of the multiple problems experienced by older 
drug users, a joined-up treatment and care approach with 
effective interagency partnerships and referrals systems 
between specialised and mainstream health and social 
services is becoming more important than ever.
users, specific health and social services for older drug users 
appear to be almost non-existent. Concerns exist about the 
lack of specific services or guidelines for this group, 
something which may have a negative impact on the 
effectiveness or access to specialised and mainstream 
services.
The scientific literature contains comparatively few reports of 
research into treatment and other health and social 
responses for older drug users. While an abundance of 
studies on treatment effectiveness has been produced in 
recent decades, few have taken age-related aspects into 
consideration.
In conclusion, the present publication highlights the need for 
policymakers in Member States to address the needs of 
ageing drug users within the framework of their drug, health 
and social policies. Drug policies are still predominantly 
geared towards the needs of younger drug users. In order to 
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